Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KOMET: Selumetinib vs placebo in adults with NF1 and symptomatic inoperable plexiform neurofibromas
jRCT2041210036Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2022
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) comparing Selumetinib with Placebo (2 arms). Primary endpoint: Confirmed Objective Response Rate (ORR) for Arm A. Started Jul 2022; status: active, not recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on jRCT2041210036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210036.